schliessen

Filtern

 

Bibliotheken

The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab... Full description

Journal Title: Oncogenesis 26 November 2018, Vol.7(11), pp.94
Main Author: Xu, Meng-Dan
Other Authors: Liu, Lu , Wu, Meng-Yao , Jiang, Min , Shou, Liu-Mei , Wang, Wen-Jie , Wu, Jing , Zhang, Yan , Gong, Fei-Ran , Chen, Kai , Tao, Min , Zhi, Qiaoming , Li, Wei
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 2157-9024 ; PMID: 30478299 Version:1 ; DOI: 10.1038/s41389-018-0102-2
Link: http://pubmed.gov/30478299
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline30478299
title: The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
format: Article
creator:
  • Xu, Meng-Dan
  • Liu, Lu
  • Wu, Meng-Yao
  • Jiang, Min
  • Shou, Liu-Mei
  • Wang, Wen-Jie
  • Wu, Jing
  • Zhang, Yan
  • Gong, Fei-Ran
  • Chen, Kai
  • Tao, Min
  • Zhi, Qiaoming
  • Li, Wei
subjects:
  • Article
ispartof: Oncogenesis, 26 November 2018, Vol.7(11), pp.94
description: Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viability and metastasis in pancreatic cancer cells. This study aims to investigate the effects of cantharidin on pancreatic cancer xenografts in vivo. Xenograft models were established using cells stably expressing luciferase. Xenograft growth was evaluated by living imaging. Gene expression was determined using a microarray, real-time PCR, a RayBiotech antibody array, and the Milliplex assay. Surprisingly, cantharidin significantly accelerated xenograft growth. Living imaging showed a rapid distribution of D-luciferin in cantharidin-treated xenografts, suggesting a rich blood supply. Immunohistochemistry confirmed increased angiogenesis. Microarray and antibody array identified upregulated proangiogenic...
language: eng
source:
identifier: ISSN: 2157-9024 ; PMID: 30478299 Version:1 ; DOI: 10.1038/s41389-018-0102-2
fulltext: fulltext
issn:
  • 21579024
  • 2157-9024
url: Link


@attributes
ID462105784
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid30478299
sourceidmedline
recordidTN_medline30478299
sourceformatXML
sourcesystemPC
pqid2138055390
display
typearticle
titleThe combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
creatorXu, Meng-Dan ; Liu, Lu ; Wu, Meng-Yao ; Jiang, Min ; Shou, Liu-Mei ; Wang, Wen-Jie ; Wu, Jing ; Zhang, Yan ; Gong, Fei-Ran ; Chen, Kai ; Tao, Min ; Zhi, Qiaoming ; Li, Wei
ispartofOncogenesis, 26 November 2018, Vol.7(11), pp.94
identifier
descriptionCantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viability and metastasis in pancreatic cancer cells. This study aims to investigate the effects of cantharidin on pancreatic cancer xenografts in vivo. Xenograft models were established using cells stably expressing luciferase. Xenograft growth was evaluated by living imaging. Gene expression was determined using a microarray, real-time PCR, a RayBiotech antibody array, and the Milliplex assay. Surprisingly, cantharidin significantly accelerated xenograft growth. Living imaging showed a rapid distribution of D-luciferin in cantharidin-treated xenografts, suggesting a rich blood supply. Immunohistochemistry confirmed increased angiogenesis. Microarray and antibody array identified upregulated proangiogenic...
languageeng
source
subjectArticle;
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/30478299$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Xu, Meng-Dan
1Liu, Lu
2Wu, Meng-Yao
3Jiang, Min
4Shou, Liu-Mei
5Wang, Wen-Jie
6Wu, Jing
7Zhang, Yan
8Gong, Fei-Ran
9Chen, Kai
10Tao, Min
11Zhi, Qiaoming
12Li, Wei
titleThe combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
descriptionCantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viability and metastasis in pancreatic cancer cells. This study aims to investigate the effects of cantharidin on pancreatic cancer xenografts in vivo. Xenograft models were established using cells stably expressing luciferase. Xenograft growth was evaluated by living imaging. Gene expression was determined using a microarray, real-time PCR, a RayBiotech antibody array, and the Milliplex assay. Surprisingly, cantharidin significantly accelerated xenograft growth. Living imaging showed a rapid distribution of D-luciferin in cantharidin-treated xenografts, suggesting a rich blood supply. Immunohistochemistry confirmed increased angiogenesis. Microarray and antibody array identified upregulated proangiogenic...
general
030478299
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1038/s41389-018-0102-2
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline30478299
issn
021579024
12157-9024
rsrctypearticle
creationdate2018
addtitleOncogenesis
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr4120181126
citationpf 94 vol 7 issue 11
startdate20181126
enddate20181126
lsr30VSR-Enriched:[subject, pqid]
sort
titleThe combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
authorXu, Meng-Dan ; Liu, Lu ; Wu, Meng-Yao ; Jiang, Min ; Shou, Liu-Mei ; Wang, Wen-Jie ; Wu, Jing ; Zhang, Yan ; Gong, Fei-Ran ; Chen, Kai ; Tao, Min ; Zhi, Qiaoming ; Li, Wei
creationdate20181126
lso0120181126
facets
frbrgroupid2104210813244802079
frbrtype5
newrecords20190701
languageeng
creationdate2018
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Xu, Meng-Dan
1Liu, Lu
2Wu, Meng-Yao
3Jiang, Min
4Shou, Liu-Mei
5Wang, Wen-Jie
6Wu, Jing
7Zhang, Yan
8Gong, Fei-Ran
9Chen, Kai
10Tao, Min
11Zhi, Qiaoming
12Li, Wei
jtitleOncogenesis
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Xu
1Liu
2Wu
3Jiang
4Shou
5Wang
6Zhang
7Gong
8Chen
9Tao
10Zhi
11Li
aufirst
0Meng-Dan
1Lu
2Meng-Yao
3Min
4Liu-Mei
5Wen-Jie
6Jing
7Yan
8Fei-Ran
9Kai
10Qiaoming
11Wei
au
0Xu, Meng-Dan
1Liu, Lu
2Wu, Meng-Yao
3Jiang, Min
4Shou, Liu-Mei
5Wang, Wen-Jie
6Wu, Jing
7Zhang, Yan
8Gong, Fei-Ran
9Chen, Kai
10Tao, Min
11Zhi, Qiaoming
12Li, Wei
atitleThe combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
jtitleOncogenesis
risdate20181126
volume7
issue11
spage94
pages94
issn2157-9024
formatjournal
genrearticle
ristypeJOUR
abstractCantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viability and metastasis in pancreatic cancer cells. This study aims to investigate the effects of cantharidin on pancreatic cancer xenografts in vivo. Xenograft models were established using cells stably expressing luciferase. Xenograft growth was evaluated by living imaging. Gene expression was determined using a microarray, real-time PCR, a RayBiotech antibody array, and the Milliplex assay. Surprisingly, cantharidin significantly accelerated xenograft growth. Living imaging showed a rapid distribution of D-luciferin in cantharidin-treated xenografts, suggesting a rich blood supply. Immunohistochemistry confirmed increased angiogenesis. Microarray and antibody array identified upregulated proangiogenic...
doi10.1038/s41389-018-0102-2
pmid30478299
date2018-11-26